|
Zebrafish Models of Cancer
|
ZIA BC 010549
|
$135,464
|
$27,093
|
Hickstein, Dennis
|
CCR (NCI)
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-07S1
|
$37,430
|
$374
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
5P30CA138292-07
|
$1,560,000
|
$15,600
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy of Cancer
|
5R01CA044722-25
|
$222,013
|
$111,007
|
STUDZINSKI, GEORGE
|
RBHS-NEW JERSEY MEDICAL SCHOOL
|
|
Validation of the Pre-BCR Signaling Complex in pre-B ALL Cell Model by Two-Color
|
1F31CA192848-01
|
$29,887
|
$29,887
|
ERASMUS, MICHAEL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
Validation and Development of WEE1 as a therapeutic target in AML
|
5R01CA172385-03
|
$316,050
|
$158,025
|
PORTER, CHRISTOPHER
|
UNIVERSITY OF COLORADO DENVER
|
|
Validating Syk as a Target for AML Therapy
|
5R01CA140292-07
|
$387,731
|
$387,731
|
STEGMAIER, KIMBERLY
|
DANA-FARBER CANCER INST
|
|
Using game mechanics to improve outcomes among stem cell transplant survivors
|
2R42CA168107-02
|
$616,412
|
$308,206
|
MCLAUGHLIN, JEFFERY
|
RADIANT CREATIVE GROUP, LLC
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S1
|
$62,500
|
$3,125
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
3P30CA014089-40S2
|
$50,000
|
$2,500
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (CORE) Support
|
5P30CA014089-40
|
$6,231,178
|
$311,559
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Unleashing the Efficacy of PI3K/AKT/mTOR Pathway Inhibitors in B-ALL
|
5F32CA189629-02
|
$56,042
|
$56,042
|
VO, THANH-TRANG
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
University of New Mexico Cancer Center Support Grant
|
2P30CA118100-11
|
$1,900,889
|
$589,276
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support Grant
|
3P30CA118100-11S1
|
$113,250
|
$35,108
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support Grant
|
3P30CA118100-11S2
|
$50,000
|
$15,500
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support Grant
|
3P30CA118100-11S3
|
$250,000
|
$77,500
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support Grant
|
3P30CA118100-11S4
|
$125,000
|
$38,750
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of New Mexico Cancer Center Support Grant
|
3P30CA118100-11S5
|
$172,654
|
$53,523
|
WILLMAN, CHERYL
|
UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-18S5
|
$1,213,480
|
$60,674
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
University of California, Irvine Cancer Center Support Grant
|
3P30CA062203-18S6
|
$48,256
|
$2,413
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
Tyrosine kinase inhibitors for the treatment of childhood AML
|
2R01CA138744-06A1
|
$314,867
|
$314,867
|
BAKER, SHARYN
|
OHIO STATE UNIVERSITY
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$376,957
|
$37,696
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Tsc1/mTOR axis in immune homeostasis and tumorigenesis
|
5R01CA176624-02
|
$369,609
|
$369,609
|
CHI, HONGBO
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Transponson-based screens for genes involved in acute lymphoblastic Leukemia
|
5R01CA154998-05
|
$289,464
|
$144,732
|
FARRAR, MICHAEL
|
UNIVERSITY OF MINNESOTA
|
|
Transcriptional regulatory mechanisms in B cell development and leukemogenesis
|
5R01CA178765-03
|
$565,455
|
$565,455
|
ROEDER, ROBERT
|
ROCKEFELLER UNIVERSITY
|
|
Toxicity Monitoring on Phase III Trials with Administrative Data
|
5R01CA165277-04
|
$410,314
|
$410,314
|
APLENC, RICHARD
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Therapeutic Targeting of Leukemia-Microenvironmental Interactions
|
5R01CA166280-03
|
$318,513
|
$318,513
|
CALVI, LAURA
|
UNIVERSITY OF ROCHESTER
|
|
Therapeutic Elimination of Stem Cells for Relapsed Pediatric AML
|
5U01CA183030-02
|
$628,352
|
$628,352
|
LIU, YANG
|
CHILDREN'S RESEARCH INSTITUTE
|
|
The Role of Trisomy 21 in Hematopoiesis and Leukemogenesis
|
1F31CA196231-01
|
$29,640
|
$29,640
|
LIGGETT, LUTHER
|
UNIVERSITY OF COLORADO DENVER
|
|
The role of PHF6 in T-cell acute lymphoblastic leukemia
|
5R01CA155743-05
|
$332,000
|
$332,000
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of HO-1 in Flt3-ITD positive AML proliferation and drug resistance
|
5F32CA171905-03
|
$56,042
|
$28,021
|
IRWIN, MARY
|
UNIVERSITY OF TX MD ANDERSON CAN CTR
|
|
The Role of FBXL4 in T-cell Acute Lymphoblastic Leukemia
|
5F30CA174099-03
|
$48,120
|
$24,060
|
HAYDU, JULIE-ERIKA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The role of ETV6 in T-cell acute lymphoblastic leukemia
|
5R01CA172398-03
|
$332,000
|
$166,000
|
FERRANDO, ADOLFO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-21S1
|
$79,482
|
$5,564
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-21
|
$4,814,560
|
$337,019
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
The pluripotency regulator Prdm14 initiates cancer by epigenetic mechanisms
|
5R01CA163849-03
|
$329,810
|
$164,905
|
JUSTICE, MONICA
|
HOSPITAL FOR SICK CHLDRN (TORONTO)
|
|
The COMPASS family of H3K4 methylases in development and cancer
|
7R01CA150265-07
|
$490,235
|
$490,235
|
SHILATIFARD, ALI
|
NORTHWESTERN UNIVERSITY AT CHICAGO
|
|
Temporal and Spatial Control of V(D)J Recombination
|
5R01CA160256-04
|
$336,150
|
$336,150
|
DESIDERIO, STEPHEN
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting to Epigenetic Modications in ALL
|
5R01CA176745-05
|
$402,250
|
$402,250
|
ARMSTRONG, SCOTT
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
Targeting SYK Tyrosine Kinase to Overcome Radiation Resistance in ALL
|
5R01CA154471-05
|
$332,000
|
$332,000
|
UCKUN, FATIH
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Targeting non-classical oncogenes as therapy for T-ALL
|
5R01CA169162-04
|
$332,000
|
$166,000
|
DIACOVO, THOMAS
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Targeting Leukemia Stem Cells with Dietary Selenium
|
5R01CA162665-04
|
$303,222
|
$303,222
|
PRABHU, KUMBLE
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
Targeting Chromatin Modifications in Leukemia with Trisomy 21
|
5K08CA181340-02
|
$155,991
|
$77,996
|
LANE, ANDREW
|
DANA-FARBER CANCER INST
|
|
Targeting BCL6 in tyrosine kinase-driven leukemia
|
5R01CA169458-03
|
$328,714
|
$164,357
|
MUSCHEN, MARKUS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Targeted therapy of B cell malignances with CAR-T cells of defined composition
|
5R01CA136551-07
|
$560,424
|
$280,212
|
RIDDELL, STANLEY
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Targeted Improvement in Stem Cell Therapy for Leukemia and Bone Marrow Failure Sy
|
5R01CA157537-05
|
$317,475
|
$317,475
|
PANG, QISHEN
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
Significance of Marrow Karyotypes in Inherited Bone Marrow Failure Syndromes
|
ZIA BC 010692
|
$38,443
|
$7,689
|
Arthur, Diane
|
CCR (NCI)
|
|
Role of TET proteins in myeloid malignancies
|
5R01CA151535-04
|
$370,180
|
$129,563
|
RAO, ANJANA
|
LA JOLLA INST FOR ALLERGY & IMMUNOLGY
|
|
Role of IKAROS in the Biology and Therapy of High-Risk Precursor B-Cell Leukemia
|
1R01CA190964-01
|
$557,731
|
$278,866
|
VAN ETTEN, RICHARD
|
UNIVERSITY OF CALIFORNIA-IRVINE
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-14
|
$270,000
|
$135,000
|
MIVECHI, NAHID
|
GEORGIA REGENTS UNIVERSITY
|
Total relevant funding to Childhood Leukemia for this search: $53,575,329
|